



MEMORANDUM

TO: Valued STAR and CHIP Providers

FROM: El Paso Health

DATE: 3/22/2024

RE: Change in PDL Status for Antivirals, Oral Drug Class Effective March 7

HHSC is aware of a drug shortage for the brand name Valcyte tablets in the "Antivirals, oral" drug class due to a change in the product's manufacturer. We received reports of the shortage and manufacturer change from MCOs, which we verified on the American Society of HealthSystem Pharmacists (ASHP) website.

Effective March 7, 2024, HHSC has removed the non-preferred status from the generic valganciclovir tablets on the preferred drug list (PDL).

This change is in response to the shortage of the preferred brand name product Valcyte tablets. The preferred status of Valcyte tablets will not change so that existing stock may be used.

Providers can now prescribe valganciclovir tablets without requiring a PDL prior authorization, which will allow clients continued access to the necessary medication.

The non-preferred status of the following drugs was removed.

NDC	Drug Name
00904679604	VALGANCICLOVIR 450 MG TABLET
00904679610	VALGANCICLOVIR 450 MG TABLET
27241015860	VALGANCICLOVIR 450 MG TABLET
31722083260	VALGANCICLOVIR 450 MG TABLET



MEMORANDUM

55111076260	VALGANCICLOVIR 450 MG TABLET
64380015301	VALGANCICLOVIR 450 MG TABLET
65862075360	VALGANCICLOVIR 450 MG TABLET

If you have any questions regarding this communication please contact our Provider Relations team at 915-532-3778 or email us at ProviderRelationsDG@elpasohealth.com